SOURCE: Novacea

March 22, 2007 08:30 ET

Novacea to Present at Future Leaders in Biotech Conference

Novacea Announces Conference Call to Discuss Fourth Quarter and Year End 2006 Financial Results

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- March 22, 2007 -- Novacea, Inc. (NASDAQ: NOVC) today announced that John P. Walker, the company's chairman and interim chief executive officer, will be presenting a company overview at the upcoming BioCentury and Thomson Financial Future Leaders in the Biotech Industry Conference to be held at the Millennium Broadway Hotel, New York. The presentation will be webcast live at 11:30 a.m. Eastern Time (ET) on Thursday, March 29, 2007. The live webcast of the presentation will be available on the Investor Relations section of Novacea's website,, and a replay will be available for 21 days thereafter.

Fourth Quarter and Year End 2006 Financial Results Conference Call Date and Dial-in information

Members of Novacea's management team will review its 2006 financial results via a webcast and conference call on March 26, 2007 at 4:30 PM ET. The webcast can be accessed via the Investor Relations section of Novacea's website at The live audio of the conference call is also accessible by telephone to investors, members of the news media and the general public by dialing either 866-713-8563 (United States and Canada) or 617-597-5311 (International) and typing in the passcode 81203279.

An archived replay of the webcast will be available via Novacea's website until April 30, 2007. The replay will also be available via telephone by dialing 888-286-8010 (United States and Canada) or 617-801-6888 (International) and typing in the passcode 79451898 until April 30, 2007.

About Novacea

Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates in clinical trials, including Asentar™, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea's second product candidate, AQ4N, is a hypoxia-activated prodrug and is being investigated in combination with radiation and chemotherapy in a Phase 1/2 clinical trial in brain tumors such as glioblastoma multiforme.

Contact Information